Caroline Palomeque
Stock Analyst at Maxim Group
(2.60)
# 2,076
Out of 4,786 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $2.89 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $33.19 | +77.76% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $180.30 | -14.59% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $63.81 | -9.11% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $155.86 | +6.51% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $13.60 | +186.87% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $7.15 | +753.15% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $8.58 | +366.20% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.89
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $33.19
Upside: +77.76%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $180.30
Upside: -14.59%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $63.81
Upside: -9.11%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $155.86
Upside: +6.51%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $13.60
Upside: +186.87%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $7.15
Upside: +753.15%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $8.58
Upside: +366.20%